ArticleCase reports in transplantation2026
BK Polyomavirus-Associated Nephropathy Complicated by Life-Threatening Hemorrhagic Pericardial Effusion Following Immunosuppression Reduction in a Kidney Transplant Recipient: A Case Report.
Article in Case reports in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: BK polyomavirus (BKPyV) is an opportunistic infection following kidney transplantation due to immunosuppression. It is a recognized cause of tubulitis and graft dysfunction in kidney transplant recipients (KTRs). Management is challenging because clinicians must balance viral control with the risk of acute rejection. This report highlights the importance of individualized therapy in a 63-year-old KTR who developed BK polyomavirus-associated nephropathy (BKPyVAN) after treatment for acute rejection. Case Report: A 63-year-old man with end-stage renal disease secondary to long-term NSAID use underwent a living-donor kidney transplant at Alzahra Hospital, Isfahan, Iran. He was maintained on tacrolimus, mycophenolate mofetil (MMF), and prednisolone. At 5 months posttransplant, he developed acute cellular rejection treated with antithymocyte globulin (Thymoglobulin). Two months later, BKPyV viremia was detected (23,700 copies/mL). Immunosuppression was modified by switching tacrolimus to cyclosporine and discontinuing MMF. Two doses of intravenous immunoglobulin (IVIG; 2 g/kg total) were administered but discontinued due to fluid overload requiring temporary hemodialysis. Subsequently, the patient developed a large hemorrhagic pericardial effusion (7 × 12 cm) with left ventricular compression, likely attributable to a combination of fluid overload, uremia, and volume shifts during renal replacement therapy, requiring urgent pericardiocentesis with drainage of 550 mL of hemorrhagic fluid. By 10 months posttransplant, renal function stabilized (serum creatinine 2.3 mg/dL) and BKPyV PCR became undetectable. Conclusions: This case highlights a rare and life-threatening complication, namely hemorrhagic pericardial effusion, arising during the management of BKPyVAN in a KTR. It underscores the importance of close cardiovascular monitoring, individualized immunosuppressive adjustment, and multidisciplinary care in this complex patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.